mp.weixin.qq.com·· 7 hours agoScore52
Roche Q3 2026 Beats Expectations and Drops Allogeneic CD19×CD20 CAR-T RG6540
In brief
Roche's Q3 2026 results beat expectations, with sales of CHF 16.13 billion, up 7% at constant exchange rates and 8% in Swiss francs, while it dropped the allogeneic CD19×CD20 CAR-T RG6540. RG6540 was one of the clinical-stage therapies named in Roche's $1.5 billion acquisition of Poseida in 2024. Group sales for the first nine months were CHF 46.493 billion, up 6% at constant exchange rates; Roche retains RG6538 from the same platform and continues autoimmune cell therapy work.
Source: mp.weixin.qq.com · mp.weixin.qq.com